ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Mar 2020 07:00 AM
RNS
Block Listing Review and Total Voting Rights
24 Feb 2020 07:00 AM
RNS
Positive long-term data in retinal clinical trial
17 Feb 2020 07:00 AM
RNS
Positive Phase 2a stroke clinical data published
12 Feb 2020 07:02 AM
RNS
Notification of Major Holdings
12 Feb 2020 07:01 AM
RNS
Notification of Major Holdings
12 Feb 2020 07:00 AM
RNS
Notification of Major Holdings
07 Feb 2020 01:15 PM
RNS
Notification of Major Holdings
06 Feb 2020 09:51 AM
RNS
Notification of Major Holdings
02 Jan 2020 07:00 AM
RNS
Total Voting Rights
18 Dec 2019 12:10 PM
RNS
Notification of Major Holdings
16 Dec 2019 03:00 PM
RNS
NOTIFICATION OF MAJOR HOLDINGS
06 Dec 2019 07:00 AM
RNS
Interim Results
18 Nov 2019 07:00 AM
RNS
Notification of Interim Results
23 Oct 2019 07:00 AM
RNS
ReNeuron's lead cell line shows further potential
17 Oct 2019 05:36 PM
RNS
Notification of Major Holdings
17 Oct 2019 03:21 PM
RNS
Notification of Major Holdings
14 Oct 2019 07:00 AM
RNS
Positive clinical data presented at AAO meeting
02 Oct 2019 04:40 PM
RNS
Second Price Monitoring Extn
02 Oct 2019 04:35 PM
RNS
Price Monitoring Extension
02 Oct 2019 07:00 AM
RNS
Clinical Update and Conference Presentations
12 Sep 2019 11:21 AM
RNS
Result of AGM
10 Sep 2019 07:00 AM
RNS
AGM Trading Update
02 Sep 2019 07:00 AM
RNS
Block Listing Review and TVR
21 Aug 2019 07:00 AM
RNS
Appointments to Scientific Advisory Board
14 Aug 2019 07:00 AM
RNS
Grant-funded collaboration with exosome platform
02 Aug 2019 04:00 PM
RNS
Posting of Annual Report and Notice of AGM
02 Aug 2019 01:12 PM
RNS
Notification of Major Holdings
01 Aug 2019 11:50 AM
RNS
Total Voting Rights
17 Jul 2019 07:00 AM
RNS
Director/PDMR Interest in Shares & Share Options
16 Jul 2019 07:00 AM
RNS
Key patent grants expand exosome IP portfolio
12 Jul 2019 07:00 AM
RNS
Senior business development appointment
11 Jul 2019 07:00 AM
RNS
Preliminary Results
08 Jul 2019 04:30 PM
RNS
Notification of Major Holdings
01 Jul 2019 11:00 AM
RNS
Price Monitoring Extension
01 Jul 2019 07:00 AM
RNS
Total Voting Rights
18 Jun 2019 04:01 PM
RNS
Notification of Major Holdings
18 Jun 2019 07:00 AM
RNS
Webcast of Preliminary Results
14 Jun 2019 11:09 AM
RNS
ReNeuron wins Breakthrough of the Year Award
03 Jun 2019 07:00 AM
RNS
Total Voting Rights
31 May 2019 07:00 AM
RNS
Jefferies 2019 Global Healthcare Conference
09 May 2019 05:05 PM
RNS
Exercise of options, PDMR dealing and TVR
08 May 2019 07:00 AM
RNS
Year-end update and results notification
02 May 2019 03:43 PM
RNS
Total Voting Rights
26 Apr 2019 04:40 PM
RNS
Second Price Monitoring Extn
26 Apr 2019 04:35 PM
RNS
Price Monitoring Extension
26 Apr 2019 07:00 AM
RNS
Clinical update and conference presentation
18 Apr 2019 03:40 PM
RNS
Share Purchases by Directors
12 Apr 2019 02:36 PM
RNS
Exercise of Share Options and TVR
11 Apr 2019 04:31 PM
RNS
Share Purchases by Directors
10 Apr 2019 02:37 PM
RNS
Director/PDMR Shares and Share Options

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings